Baskhanbiopharma (XKRX:354390) EV-to-FCF : 44.10 (As of Dec. 16, 2024)

Baskhanbiopharma EV-to-FCF Chart

Competitive Comparison of Baskhanbiopharma's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Baskhanbiopharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Baskhanbiopharma's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Baskhanbiopharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Baskhanbiopharma's EV-to-FCF falls into.

Baskhanbiopharma EV-to-FCF Calculation

Baskhanbiopharma's EV-to-FCF for today is calculated as:

Baskhanbiopharma's current Enterprise Value is ₩29,824 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Baskhanbiopharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was ₩676 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Baskhanbiopharma  (XKRX:354390) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Baskhanbiopharma's PE Ratio (TTM) for today is calculated as:

Baskhanbiopharma's share price for today is ₩4495.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Baskhanbiopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩396.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Baskhanbiopharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Baskhanbiopharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Baskhanbiopharma Business Description